Modular RNA Design Concept

By establishing this modular system,we can achieve the flexible combination and optimization of various functional units while ensuring the compatibility of each component, thereby providing a reliable technological foundation for the continuous development of innovative RNA products. 
Based on the modular RNA design platform, we have established a flexible and efficient R&D platform. This platform designs key RNA structural elements,including the 5' cap, 5' untranslated region (UTR), gene of interest (GOI), 3' UTR, and poly(A) tail,as independently optimizable standardized modules. 

These modules collectively regulate critical functional properties: the 5' cap enables both ribosome recruitment and evasion of innate immune recognition; the UTRs modulate translation efficiency and RNA stability through interactions between their structural motifs and RNA-binding proteins; the GOI determines the production of antigens or therapeutic proteins via codon optimization and nucleotide modification; and poly(A) tail length simultaneously regulates translational activity and resistance to exonuclease degradation.
While ensuring core functionality, we precisely regulate each module, thereby significantly enhancing R&D efficiency, shortening validation cycles, and improving technological scalability. 

Non-replicating mRNA Technology Platform

Our non-replicating mRNA technology platform features a unique dumbbell-shaped antigen design. This enables a single mRNA strand to mimic the effect of a multivalent vaccine:—where one mRNA molecule simultaneously expresses multiple viral antigen fragments. Through flexible linker design, these fragments self-assemble in vivo into multimeric structures resembling viral particles.
This structure can more effectively elicit a potent immune response.

Compared with conventional approaches, our platform eliminates the need to produce multiple mRNA strands, significantly streamlining the production process of multivalent vaccines. 

This not only enhances vaccine efficacy but also significantly reduces process complexity and manufacturing costs. 

Self-replicating RNA （srRNA）Technology Platform

Our self-replicating RNA (srRNA) technology platform incorporates a proprietary isRNA design, aiming to precisely balance three core metrics of RNA vaccines and therapeutics: antigen expression levels, expression duration and innate immune activation intensity. 

For RNA vaccines or therapies, innate immune activation is a double-edged sword: moderate activation can effectively induce a robust immune response, particularly beneficial for anti-tumor or clearing latent viruses; however, excessive activation may trigger inflammation responses and inhibit the replication and translation of the RNA itself.

To address this core challenge, our propriety isRNA design employs a dual strategy. 

Core Sequence Optimization: Through multiple engineering modifications of the replicase derived from the wild-type VEEV virus, we have significantly reduced its immunogenicity while retaining its high replication efficiency. The engineered isRNA achieved approximately 10-fold increase in target gene expression compared to the wild-type.

Advanced Manufacturing Process: We have custom-developed a comprehensive production process that effectively removes byproducts and impurities generated during RNA synthesis, thereby avoiding unnecessary or excessive innate immune activation caused by bythese process impurities.